BioNTech SE (BNTX) EV/FCF Ratio: 7.68x
Is BioNTech SE’s EV/FCF ratio high or low?
BioNTech SE's EV/FCF ratio of 7.68x is 32% below its 5-year average of 11.25x, near the low end of its 5-year range (0.93x–77.14x).
As of Wednesday, June 17, 2026. 63.81% below its 12-month average of 21.22x.
BNTX EV/FCF Ratio Chart
BNTX Average EV/FCF Ratio Chart
BNTX Current vs Average EV/FCF Ratio Chart
BNTX EV/FCF Ratio Metrics
EV/FCF RATIO
7.68x
EV/FCF RATIO AVG TTM
21.22x
EV/FCF RATIO AVG 3Y
3.91x
EV/FCF RATIO AVG 5Y
3.46x
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-63.81%
CURRENT VS 3Y AVG
+96.31%
CURRENT VS 5Y AVG
+122.10%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BNTX Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | $23.27B | 7.68x | 21.22x | 3.91x | 3.46x |
| Mettler-Toledo International Inc. (MTD)vs › | $23.27B | 32.16x | 33.79x | 33.47x | 38.34x |
| United Therapeutics Corporation (UTHR)vs › | $23.41B | 24.54x | 18.94x | 17.00x | 17.01x |
| Waters Corporation (WAT)vs › | $23.53B | 131.52x | 44.88x | 43.53x | 41.75x |
| Moderna, Inc. (MRNA)vs › | $21.98B | N/A | 26.90x | 26.23x | 26.23x |
| Labcorp Holdings Inc. (LH)vs › | $21.71B | 20.38x | 22.34x | 25.43x | 20.40x |
| Veeva Systems Inc. (VEEV)vs › | $25.96B | 15.41x | 28.41x | 32.61x | 38.01x |
| DexCom, Inc. (DXCM)vs › | $28.23B | 20.33x | 36.80x | 66.23x | 181.10x |
| Biogen Inc. (BIIB)vs › | $28.88B | 12.28x | 12.74x | 21.54x | 21.15x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.53x | 16.94x | 18.67x | 15.16x |
Cash Flow Valuation Comparison
EV/FCF
7.7x
P/FCF
15.1x
FCF Yield
6.61%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
BioNTech SE EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE EV/FCF Ratio FAQ
- What is the EV/FCF ratio for BioNTech SE (BNTX)?
- The EV/FCF ratio for BNTX stock is 7.68x.
- Is BioNTech SE's EV/FCF ratio high or low?
- BioNTech SE's EV/FCF ratio of 7.68x is 32% below its 5-year average of 11.25x, near the low end of its 5-year range (0.93x–77.14x).
- What is the TTM average EV/FCF ratio for BioNTech SE (BNTX)?
- The TTM average EV/FCF ratio for BNTX stock is 21.22x.
- What is the 3Y average EV/FCF ratio for BioNTech SE (BNTX)?
- The 3Y average EV/FCF ratio for BNTX stock is 3.91x.
- What is the 5Y average EV/FCF ratio for BioNTech SE (BNTX)?
- The 5Y average EV/FCF ratio for BNTX stock is 3.46x.
BioNTech SE EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-16 | 7.68x |
| 2026-06-15 | 7.90x |
| 2026-06-12 | 7.86x |
| 2026-06-11 | 7.69x |
| 2026-06-10 | 7.12x |
| 2026-06-09 | 7.18x |
| 2026-06-08 | 7.01x |
| 2026-06-05 | 7.44x |
| 2026-06-04 | 7.70x |
| 2026-06-03 | 7.51x |
| 2026-06-02 | 7.62x |
| 2026-06-01 | 8.06x |
| 2026-05-29 | 8.78x |
| 2026-05-28 | 8.35x |
| 2026-05-27 | 8.28x |
| 2026-05-26 | 8.15x |
| 2026-05-22 | 8.13x |
| 2026-05-21 | 7.93x |
| 2026-05-20 | 7.83x |
| 2026-05-19 | 7.40x |
| 2026-05-18 | 7.57x |
| 2026-05-15 | 7.69x |
| 2026-05-14 | 8.11x |
| 2026-05-13 | 8.15x |
| 2026-05-12 | 8.39x |
| 2026-05-11 | 8.33x |
| 2026-05-08 | 8.47x |
| 2026-05-07 | 8.28x |
| 2026-05-06 | 8.66x |
| 2026-05-05 | 8.70x |
| 2026-05-04 | 33.75x |
| 2026-05-01 | 32.80x |
| 2026-04-30 | 35.92x |
| 2026-04-29 | 34.93x |
| 2026-04-28 | 35.19x |
| 2026-04-27 | 35.19x |
| 2026-04-24 | 36.98x |
| 2026-04-23 | 37.04x |
| 2026-04-22 | 38.64x |
| 2026-04-21 | 40.23x |
| 2026-04-20 | 36.84x |
| 2026-04-17 | 35.64x |
| 2026-04-16 | 35.22x |
| 2026-04-15 | 33.82x |
| 2026-04-14 | 33.26x |
| 2026-04-13 | 32.35x |
| 2026-04-10 | 31.72x |
| 2026-04-09 | 29.86x |
| 2026-04-08 | 29.91x |
| 2026-04-07 | 28.61x |
| 2026-04-06 | 29.49x |
| 2026-04-02 | 29.44x |
| 2026-04-01 | 28.51x |
| 2026-03-31 | 28.22x |
| 2026-03-30 | 26.30x |
| 2026-03-27 | 26.53x |
| 2026-03-26 | 27.47x |
| 2026-03-25 | 28.16x |
| 2026-03-24 | 27.13x |
| 2026-03-23 | 27.97x |
| 2026-03-20 | 28.43x |
| 2026-03-19 | 28.45x |
| 2026-03-18 | 28.81x |
| 2026-03-17 | 31.38x |
| 2026-03-16 | 29.10x |
| 2026-03-13 | 29.44x |
| 2026-03-12 | 28.87x |
| 2026-03-11 | 29.26x |
| 2026-03-10 | 25.58x |
| 2024-12-30 | 10.79x |
| 2024-12-27 | 11.00x |
| 2024-12-26 | 10.97x |
| 2024-12-24 | 11.03x |
| 2024-12-23 | 10.93x |
| 2024-12-20 | 10.87x |
| 2024-12-19 | 10.60x |
| 2024-12-18 | 10.64x |
| 2024-12-17 | 11.53x |
| 2024-12-16 | 11.04x |
| 2024-12-13 | 11.99x |
| 2024-12-12 | 12.04x |
| 2024-12-11 | 11.83x |
| 2024-12-10 | 11.45x |
| 2024-12-09 | 12.06x |
| 2024-12-06 | 12.20x |
| 2024-12-05 | 11.75x |
| 2024-12-04 | 11.12x |
| 2024-12-03 | 11.25x |
| 2024-12-02 | 11.50x |
| 2024-11-29 | 11.69x |
| 2024-11-27 | 12.04x |
| 2024-11-26 | 11.71x |
| 2024-11-25 | 12.05x |
| 2024-11-22 | 10.87x |
| 2024-11-21 | 10.12x |
| 2024-11-20 | 9.18x |
| 2024-11-19 | 9.83x |
| 2024-11-18 | 9.13x |
| 2024-11-15 | 8.80x |
| 2024-11-14 | 9.40x |
| 2024-11-13 | 10.62x |
| 2024-11-12 | 9.82x |
| 2024-11-11 | 10.19x |
| 2024-11-08 | 10.49x |
| 2024-11-07 | 10.06x |
| 2024-11-06 | 9.87x |
| 2024-11-05 | 10.54x |
| 2024-11-04 | 10.23x |
| 2024-11-01 | 10.62x |
| 2024-10-31 | 10.87x |
| 2024-10-30 | 11.00x |
| 2024-10-29 | 11.01x |
| 2024-10-28 | 10.89x |
| 2024-10-25 | 10.46x |
| 2024-10-24 | 10.66x |
| 2024-10-23 | 10.54x |
| 2024-10-22 | 10.53x |
| 2024-10-21 | 10.63x |
| 2024-10-18 | 10.66x |
| 2024-10-17 | 11.08x |
| 2024-10-16 | 11.58x |
| 2024-10-15 | 11.55x |
| 2024-10-14 | 11.96x |
| 2024-10-11 | 12.01x |
| 2024-10-10 | 11.68x |
| 2024-10-09 | 11.54x |
| 2024-10-08 | 11.98x |
| 2024-10-07 | 12.17x |
| 2024-10-04 | 12.35x |
| 2024-10-03 | 11.90x |
| 2024-10-02 | 11.78x |
| 2024-10-01 | 11.92x |
| 2024-09-30 | 11.74x |
| 2024-09-27 | 5.48x |
| 2024-09-26 | 5.44x |
| 2024-09-25 | 5.30x |
| 2024-09-24 | 5.50x |
| 2024-09-23 | 5.09x |
| 2024-09-20 | 5.03x |
| 2024-09-19 | 5.05x |
| 2024-09-18 | 5.29x |
| 2024-09-17 | 5.97x |
| 2024-09-16 | 5.88x |
| 2024-09-13 | 5.87x |
| 2024-09-12 | 4.48x |
| 2024-09-11 | 4.05x |
| 2024-09-10 | 4.15x |
| 2024-09-09 | 4.15x |
| 2024-09-06 | 3.35x |
| 2024-09-05 | 3.36x |
| 2024-09-04 | 3.28x |
| 2024-09-03 | 3.20x |
| 2024-08-30 | 3.22x |
| 2024-08-29 | 3.17x |
| 2024-08-28 | 3.22x |
| 2024-08-27 | 3.13x |
| 2024-08-26 | 3.16x |
| 2024-08-23 | 3.21x |
| 2024-08-22 | 3.14x |
| 2024-08-21 | 3.28x |
| 2024-08-20 | 3.24x |
| 2024-08-19 | 3.35x |
| 2024-08-16 | 2.99x |
| 2024-08-15 | 3.14x |
| 2024-08-14 | 2.96x |
| 2024-08-13 | 2.81x |
| 2024-08-12 | 2.64x |
| 2024-08-09 | 2.66x |
| 2024-08-08 | 2.64x |
| 2024-08-07 | 2.54x |
| 2024-08-06 | 2.56x |
| 2024-08-05 | 2.47x |
| 2024-08-02 | 2.75x |
| 2024-08-01 | 2.65x |
| 2024-07-31 | 3.06x |
| 2024-07-30 | 3.11x |
| 2024-07-29 | 3.10x |
| 2024-07-26 | 3.04x |
| 2024-07-25 | 2.95x |
| 2024-07-24 | 2.83x |
| 2024-07-23 | 3.01x |
| 2024-07-22 | 3.06x |
| 2024-07-19 | 3.01x |
| 2024-07-18 | 3.08x |
| 2024-07-17 | 3.09x |
| 2024-07-16 | 3.11x |
| 2024-07-15 | 2.92x |
| 2024-07-12 | 2.97x |
| 2024-07-11 | 2.95x |
| 2024-07-10 | 2.69x |
| 2024-07-09 | 2.64x |
| 2024-07-08 | 2.63x |
| 2024-07-05 | 2.60x |
| 2024-07-03 | 2.59x |
| 2024-07-02 | 2.50x |
| 2024-07-01 | 2.51x |
| 2024-06-28 | 2.62x |
| 2024-06-27 | 1.69x |
| 2024-06-26 | 1.77x |
| 2024-06-25 | 1.85x |
| 2024-06-24 | 1.94x |
| 2024-06-21 | 1.86x |
| 2024-06-20 | 1.91x |
| 2024-06-18 | 1.93x |
| 2024-06-17 | 2.02x |
| 2024-06-14 | 2.16x |
| 2024-06-13 | 2.33x |
| 2024-06-12 | 2.40x |
| 2024-06-11 | 2.44x |
| 2024-06-10 | 2.41x |
| 2024-06-07 | 2.50x |
| 2024-06-06 | 2.56x |
| 2024-06-05 | 2.59x |
| 2024-06-04 | 2.47x |
| 2024-06-03 | 2.61x |
| 2024-05-31 | 2.51x |
| 2024-05-30 | 2.44x |
| 2024-05-29 | 2.21x |
| 2024-05-28 | 2.25x |
| 2024-05-24 | 2.36x |
| 2024-05-23 | 2.45x |
| 2024-05-22 | 2.58x |
| 2024-05-21 | 2.16x |
| 2024-05-20 | 2.18x |
| 2024-05-17 | 2.10x |
| 2024-05-16 | 2.20x |
| 2024-05-15 | 2.17x |
| 2024-05-14 | 2.17x |
| 2024-05-13 | 2.19x |
| 2024-05-10 | 2.15x |
| 2024-05-09 | 2.16x |
| 2024-05-08 | 2.08x |
| 2024-05-07 | 2.12x |
| 2024-05-06 | 2.22x |
| 2024-05-03 | 2.19x |
| 2024-05-02 | 2.17x |
| 2024-05-01 | 2.08x |
| 2024-04-30 | 2.03x |
| 2024-04-29 | 2.00x |
| 2024-04-26 | 1.97x |
| 2024-04-25 | 1.94x |
| 2024-04-24 | 2.00x |
| 2024-04-23 | 2.02x |
| 2024-04-22 | 2.00x |
| 2024-04-19 | 1.95x |
| 2024-04-18 | 1.92x |
| 2024-04-17 | 1.93x |
| 2024-04-16 | 1.93x |
| 2024-04-15 | 1.99x |
| 2024-04-12 | 1.94x |
| 2024-04-11 | 1.96x |
| 2024-04-10 | 2.02x |
| 2024-04-09 | 2.08x |
| 2024-04-08 | 2.05x |
| 2024-04-05 | 2.10x |
| 2024-04-04 | 2.08x |
| 2024-04-03 | 2.11x |
| 2024-04-02 | 2.14x |
| 2024-04-01 | 2.21x |
| 2024-03-28 | 1.71x |
Showing the most recent 260 of 886 data points. The chart above shows the full history.
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin